Reassessing Treatment Outcomes Following Immune-Related Adverse Events

Дата публикации: 01-07-2026 00:00:00

To the Editor The article by Block et al suggests an immediate dramatic effect of dupilumab on mortality following a cutaneous immune-related adverse event. They found that within 200 days of initiation, approximately 17% of patients given systemic corticosteroids died whereas 3% of those given dupilumab died (a risk difference of 14%). Such an immediate separation of survival curves in an observational study of cutaneous drug reactions strongly suggests unmeasured confounding, which is likely, given the inability to adjust for oncologic variables and year of treatment.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Reassessing Treatment Outcomes Following Immune-Related Adverse Events—Reply	0	10.34	01-07-2026
2	A Dermatologist’s Perspective on Cutaneous Adverse Effects in CTCAE Version 6.0	0	10.95	01-07-2026
3	В Швеции зарегистрировали 68 тыс. жалоб на побочные эффекты вакцин против COVID-19	0	0	25-08-2021
4	Caution in Interpreting Survival After for Salvage Focal Therapy vs Salvage Radical Prostatectomy	0	8.37	01-07-2026
5	Temporal Trends in Lung Cancer Cases Diagnosed at Early Stage	0	5.63	01-07-2026
6	Treatment Delays in Early Age–Onset Colorectal Cancer	0	8.3	01-07-2026
7	Caution in Interpreting Survival After for Salvage Focal Therapy vs Salvage Radical Prostatectomy	0	6.4	01-07-2026
8	Should Risk of Bias Be Assessed at the Outcome Level?	0	8.24	01-07-2026
9	В Британии число умерших от стрептококковой инфекции детей выросло до 15	0	0	08-12-2022
10	В Австрии 55 человек умерли после прививки от коронавируса за время вакцинации	0	0	30-03-2021

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10.29. Источник: jamanetwork.com.